In recent years, lentiviral expression systems have gained an unmatched reputation among the gene therapy community for their ability to deliver therapeutic transgenes into a wide variety of dif®cult-totransfect/transduce target tissues (brain, hematopoietic system, liver, lung, retina) without eliciting signi®cant humoral immune responses. We have cloned a construction kit-like self-inactivating lentiviral expression vector family which is compatible to state-of-the-art packaging and pseudotyping technologies and contains, besides essential cisacting lentiviral sequences, (i) unparalleled polylinkers with up to 29 unique sites for restriction endonucleases, many of which recognize 8 bp motifs, (ii) strong promoters derived from the human cytomegalovirus immediate-early promoter (P hCMV ) or the human elongation factor 1a (P hEF1a ), (iii) P hCMV± or P PGK± (phosphoglycerate kinase promoter) driven G418 resistance markers or uorescent protein-based expression tracers and (iv) tricistronic expression cassettes for coordinated expression of up to three transgenes. In addition, we have designed a size-optimized series of highly modular lentiviral expression vectors (pLentiModule) which contain, besides the extensive central polylinker, unique restriction sites¯anking any of the 5¢U3, R-U5-y+-SD, cPPT-RRE-SA and 3¢LTR DU3 modules or placed within the 5¢U3 (±78 bp) and 3¢LTR DU3 (8666 bp). pLentiModule enables straightforward cassette-type module swapping between lentiviral expression vector family members and facilitates the design of Tat-independent (replacement of 5¢LTR by heterologous promoter elements), regulated and self-excisable proviruses (insertion of responsive operators or LoxP in the 3¢LTR DU3 element). We have validated our lentiviral expression vectors by transduction of a variety of insect, chicken, murine and human cell lines as well as adult rat cardiomyocytes, rat hippocampal slices and chicken embryos. The novel multi-purpose construction kit-like vector series described here is compatible with itself as well as many other (nonviral) mammalian expression vectors for straightforward exchange of key components (e.g. promoters, LTRs, resistance genes) and will assist the gene therapy and tissue engineering communities in developing lentiviral expression vectors tailored for optimal treatment of prominent human diseases.
INTRODUCTION
Gene therapy strategies rely on ef®cient transfer of therapeutic transgenes into desired target cells. A variety of viral and nonviral vectors and expression concepts have been designed and evaluated for their safety, high-level transduction, tropism and sustained expression in a variety of therapeutically relevant cells and tissues (1, 2) . Retroviral vectors derived from oncoretroviruses such as the murine leukemia virus (MLV) emerged as the most widely used gene therapy tools for transgene delivery currently in the clinics (3) . The attractiveness of oncoretroviral transduction technologies resides in: (i) their ability to mediate stable integration in the target chromosomes likely promoting long-term expression of delivered transgenes; (ii) their large cloning capacity suf®cient for most foreseeable clinical situations; (iii) their compatibility with pseudotyping strategies which extend the tropism of gene delivery; and (iv) the exclusive delivery of therapeutic transgenes in the absence of viral genes which precludes any potent humoral immune response eliminating transduced cells and enables recurring treatments (3, 4) .
In addition to these characteristics common to all retroviruses, lentiviruses such as the human immunode®ciency virus type 1 (HIV-1) can replicate in non-mitotic cells owing to their so-called pre-integration complex, a macromolecular structure comprising the viral genome, a few structural proteins and the enzymes responsible for reverse transcription and integration (5±7). Transduction of proliferation-incompetent cells is a decisive asset for molecular interventions in tissues considered key targets for future gene therapy including the brain, the heart, the hematopoietic system, the liver, the lungs and the retina (8±14). Like all retroviruses, the HIV-1 genome contains the gag, pol and env regions, which encode the core proteins, the virion-associated enzymes and the envelope (Env) glycoprotein (13, 15) . This coding region is anked by the long terminal repeats (LTRs; 5¢ and 3¢LTR) and cis-acting sequences essential for integration, transcription and polyadenylation. In addition, HIV-1 contains two regulatory genes, tat and rev, required for viral replication (LTR transactivation and nuclear export of viral RNA) and four accessory genes, vif, vpr, vpu and nef, which are dispensable for viral growth but critical for in vivo replication and pathogenesis (15) . Basal transcription of the HIV-1 provirus' 5¢LTR initially results in small amounts of multiply spliced transcripts encoding Tat, Rev and Nef. Tat transactivates 5¢LTR-mediated transcription until Rev reaches a threshold concentration and mediates cytoplasmic accumulation of unspliced and singly spliced viral transcripts followed by production of the late viral proteins (15) .
Capitalizing on a re®ned understanding of HIV-1 molecular biology following decades of intensive research on acquired immunode®ciencies, a group of researchers pioneered the transition of this well-evolved pathogen into a high leverage gene therapy tool (16±18). HIV-1-based vectors have been generated using a multiply attenuated packaging system, which is activated in its most advanced third generation con®guration by transient transfection of four plasmids encoding: (i) gag (coding for the virion main structural proteins) and pol (responsible for lentivirus-speci®c enzymes); (ii) rev (a post-transcriptional regulator for gag and pol expression as well as nuclear RNA export); (iii) vsv-g (required for pseudotyping); and (iv) the desired transgene in a lentiviral expression con®guration (lentiviral expression vector or lentivector) (19) . Latest developments include packaging cell lines, which express all packaging components and require exclusive transfection of the lentiviral expression vector (20±23). The lentiviral expression vector, which can be combined with any generation of packaging system, is the only genetic material transferred to the target cell. It typically comprises the transgene cassette¯anked by cis-acting elements required for encapsidation, reverse transcription and integration including the packaging signal (y+), the polypurine tracts (PPT), 5¢ and 3¢LTRs as well as env-derived sequences encompassing the Rev response element (RRE) (16±19,24). Latest generation HIV-1-based expression technologies include self-inactivating (SIN) vectors, which loose the transcriptional capacity of the LTR once integrated into target cells. SIN vectors show improved performance and are devoid of transcriptional interference and in vivo suppression associated with standard vectors and enable construction of more-stringent tissue-speci®c and/or regulatable expression con®gurations (25, 26) .
Unfortunately, current lentiviral expression vectors are the result of a progressive development rather than a bottom-up rational design and are therefore often lacking convenient multiple cloning sites (MCS) and a modular set-up to increase compatibility with existing expression technologies (gene regulation, recombination) (16, 17, 19) . This situation has signi®cantly delayed the dissemination of lentiviral expression technology beyond the pioneering laboratories to a broad scienti®c community. We describe here a size-optimized highly modular construction kit of SIN lentiviral expression vectors containing extended MCS, multicistronic expression cassettes as well as various promoter and resistance elements.
MATERIALS AND METHODS

Cell culture and¯uorescence microscopy
Chinese hamster ovary cells (CHO-K1; ATCC CCL-61), baby hamster kidney cells BHK-21 (ATCC CCL-10), human ®brosarcoma cells HT-1080 (ATCC CCL-121), human cervical adenocarcinoma cells HeLa (ATCC CCL-2), human hepatocellular carcinoma cells HepG2 (ATCC HB-8065) and human chronic myelogenous leukemia cell line K-562 (ATCC-243) were cultivated in FMX-8 (Cell Culture Technologies GmbH, Switzerland), Dulbecco's modi®ed Eagle medium (DMEM) (BHK-21, HT-1080, HeLa, HepG2; catalog no. 52100-039; Life Technologies AG, Basel, Switzerland) or Iscove's modi®ed Dulbecco's medium (K-562, catalog no. 4220-022; Life Technologies AG) supplemented with 10% fetal calf serum (all other cell lines; PAA Vienna, Austria; Lot. no. A01129-242). The chicken bursal cell line DT40 was cultivated as described before (27) . Adult rat cardiomyocytes (ARC) were prepared and cultivated as described previously (28) . Hippocampal slices prepared from 6-day postnatal rats were cultured using the roller-tube technique (29) .
For DRAQ5-mediated DNA-speci®c staining of transduced cells, 4 Q 10 3 CHO-K1 cells were seeded into chamber slides (Lab-Tek, Nalge Nunc International, IL) and grown for 24 h before they were infected with 2 Q 10 6 c.f.u./ml of desired lentiviruses (pMF365-, pBM40-and pBM45-derived). After 48 h, DRAQ5 (Biostatus Ltd, Leicestershire, UK) was added to the culture at a ®nal concentration of 25 mM for 7 min. The medium was removed and cells washed twice with PBS (Dulbecco's phosphate-buffered saline, Sigma, catalog no. D5773) before they were ®xed with 4% paraformaldehyde in PBS for 8 min and washed another ®ve times with PBS. After removing the PBS, the cells were covered with a drop of Lisbeth's medium [Tris-buffered glycerol: 3:7 mixture of 0.1 M Tris±HCl (pH 9.5) and glycerol plus 50 mg/ml npropyl-gallat] and sealed with a cover slip for confocal microscopy.
Expression of¯uorescent proteins was visualized using a Leica DM-RB¯uorescence microscope (Heerbrugg, Switzerland) or a confocal microscope set-up (Zeiss Axioplan¯uorescence microscope, Biorad MRC-600 confocal scanner, Silicon Graphics workstation) equipped with appropriate ®lters. The¯uorescence of the enhanced green uorescent protein (EGFP) and the enhanced yellow¯uores-cent protein (EYFP) were visualized using the XF114 ®lter (Omega Optical Inc., Brattleboro, VT), the enhanced cyan uorescent protein (ECFP) was detected using the XF105 ®lter (Omega Optical Inc.) and the red¯uorescent protein was monitored using the N2.1 ®lter by Leica Inc (Heerbrugg, Switzerland). 
In vivo transduction of chicken embryos
Experiments on chicken embryos were conducted following the shell-free cultivation protocols by Djonov and co-workers (30) . After 3 days of incubation at 37°C, Brown Leghorn eggs were opened, and their contents were carefully poured into plastic Petri dishes, 80 mm in diameter. The chicken embryos were incubated at 37°C in a humidi®ed atmosphere.
Recombinant lentiviruses were applied locally on the top of the growing chorioallontoic membrane (CAM) or injected intravenously at embryonic day 9. On embryonic day 11, the CAMs were examined by in vivo¯uorescence microscopy following intravenous (i.v.) injection of 0.1 ml 2.5¯uor-esceine isothiocyanate dextran (2 000 000; Sigma, St Louis, This work pBM6
The P PGK -neo cassette was ampli®ed from pMSCVneo using OBM1/OBM2 and cloned in sense orientation into pcDNA3.1/V5-His TOPO This work pMB7 P EF1a was excised from pMF320 using EcoRV/XmaI and cloned into the compatible sites (HpaI/XmaI) of pMF388 (5¢LTR-y+-ori SV40 -cPPT-RRE-P hEF1a -MCS-3¢LTR DU3 )
This work pBM8
The P PGK -neo cassette was excised from pBM6 by PacI/MluI and cloned into the corresponding sites (PacI/MluI) of pMF356 (5¢LTR-y+-ori SV40 -cPPT-RRE-MCSI-P PGK -neo-MCSII-3¢LTR DU3 )
This work pBM9
The P PGK -neo cassette was excised from pBM6 by PacI/MluI and inserted into the corresponding sites (PacI/MluI) of pMF359 (5¢LTR-y+-ori SV40 -cPPT-RRE-P EF1a -MCSI-P PGK -neo-MCSII-3¢LTR DU3 )
This work pBM13
The P PGK -neo cassette was excised from pBM6 using PacI/MluI and cloned into the corresponding sites (PacI/MluI) of pMF388 (5¢LTR-y+-ori SV40 -cPPT-RRE-MCSI-P PGK -neo-MCSII-3¢LTR DU3 )
This work pBM14
The P PGK -neo cassette was excised from pBM6 using PacI/MluI and cloned into the corresponding sites (PacI/MluI) of pBM7 (5¢LTR-y+-ori SV40 -cPPT-RRE-P EF1a -MCSI-P PGK -neo-MCSII-3¢LTR DU3 )
This work pBM40 EYFP was excised from pLentiModule4 by NheI/MluI and cloned into the compatible sites (SpeI/MluI) of pBM7 (5¢LTR-y+-ori SV40 -cPPT-RRE-P hEF1a -EYFP-3¢LTR DU3 )
This work pBM42 mEPO was excised from pMF242 by EcoRI/EcoRV and cloned into the compatible sites (EcoRI/PmeI) of pMF359 (5¢LTR-y+-ori SV40 -cPPT-RRE-P hEF1a -EPO-3¢LTR DU3 )
This work pBM43 VEGF 121 was excised from pWW265 by SalI/MluI and ligated into the corresponding sites (SalI/MluI) of pMF359 (5¢LTR-y+-ori SV40 -cPPT-RRE-P hEF1a -VEGF 121 -3¢LTR DU3 )
This work pBM44 SEAP was excised from pSS173 by EcoRI/EcoRV and ligated into the compatible sites (EcoRI/PmeI) of pMF359 (5¢LTR-y+-ori SV40 -cPPT-RRE-P hEF1a -SEAP-3¢LTR DU3 )
This work pLentiTRIDENT1 The MCSI-IRESI-MCSII-IRESII-MCSIII cassette was excised from pTRIDENT1 by EcoRI/BglII and cloned into the compatible sites (EcoRI/BamHI) of pMF363 (5¢LTR-y+-ori SV40 -cPPT-RRE-
This work pLentiTRIDENT2 The MCSI-IRES-MCSII-CITE*-MCSII cassette was excised from pTRIDENT3 by EcoRI/BglII and cloned into the compatible sites (EcoRI/BamHI) of pMF363 (5¢LTR-y+-ori SV40 -cPPT-RRE-P hCMV -MCSI-
This work pLentiTFT1
The triple-¯uorescent expression cassette ECFP-IRESI-RFP-IRESII-EYFP was excised from pWW85 using EcoRI/MluI and cloned into the corresponding sites (EcoRI/MluI) of pLentiTRIDENT1
This work pLentiTFT2 EYFP was excised from pWW85 by SpeI/MluI and cloned to the corresponding sites (SpeI/MluI) of pBM1 (5¢LTR-y+-ori SV40 -cPPT-RRE-P hCMV -ECFP-IRES-RFP-CITE*-EYFP-3¢LTR DU3 ) (pMB3)
This work pLentiModule1 PPT-3¢LTR DU3 was excised from pMF355 by MluI/XbaI and cloned into the corresponding sites
This work pLentiModule2
The P hCMV -EYFP cassette was excised from pMF351 by EcoRI/MluI and cloned into the corresponding
This work pLentiModule3 ori SV40 was excised from pMF378 by XbaI/NheI and cloned into the XbaI sites of pLentiModule1
This work pLentiModule4 ori SV40 was excised from pMF378 by XbaI/NheI and cloned into the XbaI sites of pLentiModule2
This work pLentiModule5
The P hEF1a -EYFP cassette was excised from pMF365 by BamHI and ligated in sense orientation into the corresponding site (BamHI) of pLentiModule1 (XhoI/NruI-
This work pLentiModule6
The P hEF1a -VEGF 121 cassette was excised from pBM43 by BamHI and ligated in sense oritentation into the corresponding site (BamHI) of pLentiModule1 (XhoI/NruI-
This work pLentiModule7
The P hEF1a -EPO cassette was excised from pBM42 by BamHI and ligated in sense orientation into the corresponding site (BamHI) of pLentiModule1 (XhoI/NruI-
This work pLentiModule8
The P hEF1a -SEAP cassette was excised from pBM44 by BamHI and ligated in sense orientation into the corresponding site (BamHI) of pLentiModule1 (XhoI/NruI-U3 1 -StuI/SbfI-U3 2 -SrfI-R-U5-y+-SD-SwaIcPPT-RRE-SA-P hEF1a -SEAP-DU3 1 -PmeI/HpaI/BclI-DU3 2 -NdeI/NheI/SalI/XbaI) (pBM48) (31) . The developing blood vessels were monitored using a Polyvar-Reichert¯uorescent microscope at a magni®cation of 25Q. The microscope was equipped with a custom-built heating table to maintain the temperature of the specimens at 37°C. Blood circulation and microvascular patterns were monitored for~15 min for every CAM using an LE CCD Optronics video camera (Visitron system, Puchheim, Germany) and a digital video recorder (Sony, DHR-1000 VC).
Construction of lentiviral expression vectors
Lentiviral expression vectors ( as HpaI/KpnI fragment into pNL-EGFPDU3 resulting in pMF351 (5¢LTR-y+-ori SV40 -cPPT-RRE-MCSI-P hCMV -EYFP-MCSII-3¢LTR DU3 ).
(ii) The P hCMV -EYFP cassette was eliminated from pMF351 by NotI restriction and religation, which resulted in pMF356 (5¢LTR-y+-ori SV40 -cPPT-RRE-MCS-3¢LTR DU3 ). pMF356 was further digested with PacI/MluI and the PacI/ MluI P PGK -neo (P PGK , promoter of the phosphoglycerate Figure 1 . (Previous page and above) SIN lentivectors containing optimized MCS. Generic HIV-1-derived lentivectors containing the 5¢LTR, the extended packaging signal (y+), the Simian virus 40 origin of replication (ori SV40 ), the cPPT, the RRE and the 3¢LTR with deleted enhancer sequences (3¢LTR DU3 ). The MCS was placed between RRE and 3¢LTR DU3 . Besides this basic lentivector con®guration a variety of derivatives containing different mammalian/ human promoters (P PGK , phosphoglycerate kinase promoter; P hEF1a , human elongation factor 1a promoter; P hCMV , human immediate early cytomegalovirus promoter) and reporter (EYFP and ECFP) or resistance genes (neo, G418 resistance gene) have been designed. kinase; neo, G418 resistance gene) cassette of pBM6 was inserted (pBM8; 5¢LTR-y+-ori SV40 -cPPT-RRE-MCSI-P PGKneo-MCSII-3¢LTR DU3 ). pBM6 was constructed by amplifying P PGK -neo from pMSCVneo (Clontech) using oligonucleotides OBM1: CGACTAGTTTAATTAAaattctaccgggtagggg (annealing sequence in lower case, SpeI/PacI sites are underlined) and OBM2: CGGGTACCACGCGTcctcagaagaactcgtcaag (annealing sequence in lower case, KpnI/MluI sites are underlined) and cloned in sense orientation into pcDNA3.1/V5-His TOPO (Invitrogen, Carlsbad, CA).
pMF356 derivatives containing either P hEF1a (P hEF1a , promoter of the human elongation factor 1a; pMF359) or P hCMV (pMF363) promoters were generated as follows. pMF359 (5¢LTR-y+-ori SV40 -cPPT-RRE-P hEF1a -MCS-3¢LTR DU3 ). (i) P hEF1a was ampli®ed from pEF4/MycHisB (Invitrogen) using oligonucleotides OMF164: GATCGGATCCtgcaaagatggataaagt (annealing sequence in lower case, BamHI site is underlined) and OMF165: GATC-AAGCTTTTAATTAAGCGATCGCGCCCGGGCGCGGCCGCaactagccagcttgggtc (annealing sequence in lower case, HindIII/PacI/SgfI/SrfI/SmaI/NotI sites are underlined) and cloned in antisense orientation into pcDNA3.1/V5-His TOPO (Invitrogen) to result in pMF320. P hEF1a was excised from pMF320 by EcoRV/XmaI and cloned into the compatible sites (HpaI/XmaI) of pMF356 thereby resulting in pMF359 (5¢LTR-y+-ori SV40 -cPPT-RRE-P hEF1a -MCS-3¢LTR DU3 ). (ii) EYFP was excised from pMF201 (33) by EcoRV/SpeI and cloned into the compatible sites (SmaI/SpeI) of pMF359 to result in pMF365 (5¢LTR-y+-ori SV40 -cPPT-RRE-P hEF1a -EYFP-3¢LTR DU3 ). (iii) pMF359 was restricted using PacI/ MluI and the P PGK -neo cassette excised from pBM6 by PacI/ MluI was inserted (pBM9; 5¢LTR-y+-ori SV40 -cPPT-RRE-P hEF1a -MCSI-P PGK -neo-MCSII-3¢LTR DU3 ). pMF359 derivatives include: (i) pBM42: pMF359 was restricted with EcoRI/ PmeI and EPO (erythropoietin) excised from pMF242 (33) by EcoRI/EcoRV was inserted (5¢LTR-y+-ori SV40 -cPPT-RRE-P hEF1a -EPO-3¢LTR DU3 ). (ii) pBM43: pMF359 was restricted with SalI/MluI and VEGF 121 (variant 121 of the vascular endothelial growth factor) excised from pWW265 (C.Weber and A.Zisch, unpublished data) by SalI/MluI was inserted (5¢LTR-y+-ori SV40 -cPPT-RRE-P hEF1a -VEGF 121 -3¢LTR DU3 ). (iii) pBM44: pMF359 was restricted with EcoRI/PmeI and SEAP (human placental secreted alkaline phosphatase) excised from pSS173 (34) by EcoRI/EcoRV was inserted (5¢LTR-y+-ori SV40 -cPPT-RRE-P hEF1a -SEAP-3¢LTR DU3 ). pMF363 (5¢LTR-y+-ori SV40 -cPPT-RRE-P hCMV -MCS-3¢LTR DU3 ): (i) P hCMV was excised from pLPCX (Clontech) with StuI/EcoRI and ligated to the compatible HpaI/EcoRI sites of pMF356 to result in pMF363 (5¢LTR-y+-ori SV40 -cPPT-RRE-P hCMV -MCS-3¢LTR DU3 ). (ii) ECFP was excised from pMF201 (33) by EcoRI/NotI and ligated to the corresponding sites (EcoRI/NotI) of pMF363 thereby resulting in pMF371 (5¢LTR-y+-ori SV40 -cPPT-RRE-P hCMV -ECFP-3¢LTR DU3 ).
Tricistronic pLentiTRIDENT expression vectors. pLenti-TRIDENT vectors contain a pTRIDENT-derived tricistronic expression cassette inserted in the MCS of pMF363. pLentiTRIDENT1 (pMF370; 5¢LTR-y+-ori SV40 -cPPT-RRE-P hCMV -MCSI-IRESI-MCSII-IRESII-MCSIII-3¢LTR DU3 ) was constructed by excising the MCSI-IRESI-MCSII-IRESII-MCSIII cassette from pTRIDENT1 [pMF125 (35) ] by EcoRI/BglII and cloning it into the compatible sites (EcoRI/ BamHI) of pMF363. pLentiTRIDENT1 was further restricted using EcoRI/MluI and the triple-¯uorescent expression cassette (ECFP-IRESI-RFP-IRESII-EYFP) excised from pWW85 (36) by EcoRI/MluI was inserted [pLentiTFT1 (pBM2); 5¢LTR-y+-ori SV40 -cPPT-RRE-P hCMV -ECFP-IRESI-RFP-IRESII-EYFP-3¢LTR DU3 ]. pLentiTRIDENT2 (pMF369; 5¢LTR-y+-ori SV40 -cPPT-RRE-P hCMV -MCSI-IRES-MCSII-CITE*-MCSIII-3¢LTR DU3 ) was constructed by excising the MCSI-IRES-MCSII-CITE*-MCSIII cassette from pTRIDENT3 [pMF122 (35) ] by EcoRI/BglII and cloning it into the compatible sites (EcoRI/BamHI) of pMF363. pLentiTRIDENT2 was further restricted using EcoRI/AscI and the ECFP-IRESI-RFP cassette excised from pWW85 (36) by EcoRI/AscI was inserted to result in pBM1 (5¢LTR-y+-ori SV40 -cPPT-RRE-P hCMV -ECFP-IRES-RFP-CITE*-MCSIII-3¢LTR DU3 ). Subsequently, pBM1 was digested using SpeI/MluI and the EYFP cassette excised from pWW85 by SpeI/MluI was inserted [pLentiTFT2 (pBM3); 5¢LTR-y+-ori SV40 -cPPT -RRE -P hCMV -ECFP-IRES-RFP-CITE*-EYFP-
Highly compact lentiviral expression vectors. pNL-derived lentiviral expression vectors contain super¯uous chromosomal sequences¯anking the lentiviral expression unit (32) . In order to eliminate these chromosomal sequences, the 5¢LTR-y+-ori SV40 -cPPT-RRE-MCS-3¢LTR DU3 cassette was ampli®ed from pMF356 using oligonucleotides OMF199: GATCGACGTCacttacaccaggaaaggc (annealing sequence in lower case, AatII site is underlined) and OMF200: GATCGCTAGCacctctacctcctggggg (annealing sequence in lower case, NheI site is underlined) and cloned as AatII/NheI fragment to the compatible, AatII/XbaI-restricted pTRIDENT1 [pMF125 (35) ] backbone thereby resulting in pMF388 (5¢LTR-y+-ori SV40 -cPPT-RRE-MCS-3¢LTR DU3 ). pMF388 derivatives include: (i) pMF394: pMF388 was restricted with HpaI/KpnI and the P hCMV -EYFP cassette excised from pMF351 by HpaI/KpnI was inserted (5¢LTR-y+-ori SV40 -cPPT-RRE-P hCMV -EYFP-3¢LTR DU3 ). (ii) pBM7: P hEF1a was excised from pMF320 by EcoRV/XmaI and cloned into the compatible HpaI/XmaI sites of pMF388 (5¢LTR-y+-oriSV40-cPPT-RRE-P EF1a -MCS-3¢LTR DU3 ). (iii) pBM13: pMF388 was restricted with PacI/MluI and the PacI/MluI P PGK -neo cassette excised from pBM6 was inserted (5¢LTR-y +-ori SV40 -cPPT-RRE -MCSI-P PGK -neo-MCSII-3¢LTR DU3 ). (iv) pBM14: pBM7 was restricted with PacI/MluI and the PacI/MluI P PGK -neo cassette excised from pBM6 was inserted (5¢LTR-y+-ori SV40 -cPPT-RRE-P EF1a -MCSI-P PGKneo-MCSII-3¢LTR DU3 ). (v) pBM40: pBM7 was restricted with SpeI/MluI and EYFP excised from pBM12 by NheI/MluI was inserted (5¢LTR-y+-ori SV40 -cPPT-RRE-P hEF1a -EYFP-3¢LTR DU3 ).
pLentiModule, a modular lentiviral expression vector (all sites indicated correspond to GenBank accession no. AF033819). pLentiModule consists of four minimal lentiviral modules [U3, R-U5-y+-SD, cPPT-RRE-SA, PPT-3¢LTR DU3 (DU3-R-U5)] containing unique restriction sites at their joints. These modules were independently ampli®ed from pNL-EGFPDU3 and cloned into pcDNA3.1/V5-His TOPO (Invitrogen). (i) pMF352: U3 (8631±9085) was ampli®ed using oligonucleotides OMF183, GATCCTCGAGTCGCGActggaagggctaatttgg (annealing sequence lower case, XhoI/NruI sites are underlined); and OMF184, GATCGCCCGGGCCAGTACAGGC-AAAAAGCAGCTGCTTATATGTAGCATCTGAG-GGCTCGCCACTCCCCAGTCCCGCCCAGGCCACACCTCCCTGCAGGcctggaaagtccccagcg (annealing sequence lower case, SrfI and SbfI are underlined; this primer inserts a SbfI at position 9007 of U3) (XhoI/NruI-U3 1 -SbfI-U3 2 -SrfI).
(ii) pMF376: R-U5-y+-SD (1±793) was ampli®ed from pNL-EGFPDU3 using oligonucleotides OMF185, GATCGCCCGGGCggtctctctggttagacc (annealing sequence lower case, SrfI site is underlined); and OMF193, GATCATTTAAATtttaaagttctaggtgat (annealing sequence lower case, SwaI site is underlined) (SrfI-R-U5-y+-SD-SwaI). pMF353: a shorter R-U5-y+-SD module (1±377) was ampli®ed using oligos OMF185 and OMF186: GATCATTTAAATtcattaatctaattctcc (annealing sequence lower case, SwaI site is underlined). (iii) pMF375: cPPT-RRE-SA [4330± 4475 (cPPT), 7200±8024 (RRE)] was ampli®ed using oligonucleotides OMF191, GATCATTTAAATatgcataaaagaaaaggg (annealing sequence lower case, SwaI site is underlined); and OMF192, CTAGGATCACGCGTTTAATTAAGCGATCG-CACTAGTATCGATGGCGCGCCGGCCGGCCAGGCCTGCGGCCGCGAATTCGACGTCatccgttcactaatcgaa (annealing sequence lower case, MluI/PacI/SgfI/SpeI/ClaI/AscI/FseI/ StuI/NotI/EcoRI/AatII are underlined) (SwaI-cPPT-RRE-SAMluI/PacI/SgfI/SpeI/ClaI/AscI/FseI/StuI/NotI/EcoRI/AatII). (iv) pMF355: PPT-3¢LTR DU3 (DU3-R-U5) (8615±9181 and 1±181) was ampli®ed using oligonucleotides OMF189, GATCACGCGTGGATCCAAAAGAAAAGGGGGGACT-GGAAGGGCTAATTCACTCCCAAAGAAGACAAGATGTTTAAACGTTAACTGATCActgctttttgcctgtact [annealing sequence lower case, MluI/BamHI is underlined, PPT is shown in bold; PmeI/HpaI/BclI are underlined and placed between the EcoRV/PvuII (GAT ¼ CTG, italics) ligation sites¯anking the DU3 deletion (corresponding to 8666±9066) of the 3¢LTR (25,32)]; and OMF190, GATCTCTAGAGTCGACGCTAGCCATATGctgctagagattttccaca (annealing sequence lower case, XbaI/SalI/NheI/NdeI are underlined) (MluI/BamHI -PPT -DU3 1 -PmeI/HpaI/BclI-DU3 2 -R-U5-NdeI/ NheI/SalI/XbaI).
pLentiModule was assembled on a pTRIDENT1 backbone following a four-step procedure. (i) U3 was excised from pMF352 using XhoI/SrfI and ligated to the corresponding sites (XhoI/SrfI) of pTRIDENT1 to result in pMF357. (ii) R-U5-y+-SD was excised from pMF353 and pMF376 by SrfI/SwaI and ligated into the corresponding sites (SrfI/SwaI) of pMF357 to result in pMF358 and pMF358x. (iii) cPPT-RRE-SA was excised from pMF375 using SwaI/MluI and ligated into the corresponding sites (SwaI/MluI) of pMF358 and pMF358x to result in pMF360 and pMF360x. (iv) PPT-3¢LTR DU3 was excised from pMF355 by MluI/XbaI and ligated into the corresponding sites (MluI/XbaI) of pMF360 and pMF360x to result in pMF402 and pLentiModule1 (pBM4; XhoI/NruI-U3 1 -StuI / SbfI-U3 2 -SrfI-R-U5-y + -SD-SwaI-cPPT-RRE-SAAatII/EcoRI/NotI/EagI/StuI/FseI/EagI/AscI/BssHII/ClaI/SpeI/ SgfI/PacI/MluI/BamHI-DU3 1 -PmeI/HpaI/BclI-DU3 2 -NdeI/NheI/ SalI/XbaI). plentiModule1 derivatives include the following. (i) pLentiModule2: pLentiModule1 was cut with EcoRI/MluI Figure 2 . Confocal microscopy analysis of transduction ef®ciencies of key lentivectors. CHO-K1 were transduced with 2 Q 10 6 EYFP-encoding pMF365-, pBM40-and pLentiModule-derived lentiviruses. Transduced cells were stained with the DNA-speci®c DRAQ5 dye and analyzed for YFPand DRAQ5-mediated¯uorescence by confocal microscopy (magni®cation 200Q). and the P hCMV -EYFP cassette excised from pMF351 by EcoRI/MluI was inserted to result in pLentiModule2 (pBM5) (XhoI/NruI-U3 1 -StuI/SbfI-U3 2 -SrfI-R-U5-y+-SDSwaI-cPPT -RRE -SA -P hCMV -EYFP-DU3 1 -PmeI/HpaI/BclI-DU3 2 -NdeI/NheI/SalI/XbaI). (ii) pLentiModule5: pLentiModule1 was cut with BamHI and the P hEF1a -EYFP-encoding BamHI cassette of pMF365 was inserted (pBM45) (XhoI/ NruI-U3 1 -StuI/SbfI-U3 2 -SrfI-R-U5-y+ -SD -SwaI-cPPT-RRE -SA-P hEF1a -EYFP -DU3 1 -PmeI/HpaI/BclI-DU3 2 -NdeI/ NheI/SalI/XbaI). (iii) pLentiModule6: pLentiModule1 was cut with BamHI and the P hEF1a -VEGF 121 -encoding BamHI cassette of pBM43 was inserted (pBM46) (XhoI/NruI-U3 1 -StuI/ SbfI-U3 2 -SrfI-R-U5 -y+-SD -SwaI-cPPT -RRE-SA-P hEF1a -VEGF 121 -DU3 1 -PmeI/HpaI/BclI-DU3 2 -NdeI/NheI/SalI/XbaI).
(iv) pLentiModule7: pLentiModule1 was cut with BamHI and the P hEF1a -EPO-encoding BamHI cassette of pBM42 was inserted (pBM47) (XhoI/NruI-U3 1 -StuI/SbfI-U3 2 -SrfI-R-U5-y+-SD -SwaI-cPPT-RRE-SA-P hEF1a -EPO-DU3 1 -PmeI/HpaI/ BclI-DU3 2 -NdeI/NheI/SalI/XbaI). (v) pLentiModule8: pLentiModule1 was cut with BamHI and the P hEF1a -SEAP- encoding BamHI cassette of pBM44 was inserted (pBM48) XhoI/NruI-U3 1 -StuI/SbfI-U3 2 -SrfI-R-U5-y+-SD-SwaI-cPPT-RRE -SA -P hEF1a -SEAP -DU3 1 -PmeI/HpaI/BclI-DU3 2 -NdeI/ NheI/SalI/XbaI).
In order to place the ori SV40 on pLentiModule1, this plasmid was restricted with XbaI and the ori SV40 XbaI/NheI fragment excised from pMF378 was inserted to result in pLentiModule3 (pBM15) (XhoI/NruI-U3 1 -StuI/SbfI-U3 2 -SrfI-R-U5-y+-SDSwaI-cPPT -RRE -SA -MCS -DU3 1 -PmeI/HpaI/BclI-DU3 2 -NdeI/NheI/SalI/XbaI-ori SV40 ). pMF378 was constructed by amplifying ori SV40 from pNL-EGFPDU3 using oligonucleotides OMF195: GATCTCTAGAtatgactccgcccatccc (annealing sequence lower case, XbaI site is underlined) and OMF196: GATCGCTAGCttgcaaaagcctaggcc (annealing sequence lower case, NheI sequence is underlined) and ligating it into pcDNA3.1/V5-His TOPO. Furthermore, pLentiModule2 was restricted with XbaI and the ori SV40 XbaI/NheI fragment excised from pMF378 was inserted to result in pLentiModule4 (pBM12) (XhoI/NruI-U3 1 -StuI/SbfI-U3 2 -SrfI-R-U5-y+-SD-SwaI-cPPT-RRE-SA-P hCMV -EYFP-DU3 1 -PmeI/HpaI/BclI-DU3 2 -NdeI/NheI/SalI/XbaI-ori SV40 ).
Lentivirus production and infection
For production of replication-incompetent SIN lentiviruses, a mixture containing 94 ml DMEM, 6 ml FUGENE (Roche Diagnostics AG, Rotkreuz, Switzerland), 25 mM chloroquine, 1 mg pLTR-G [encoding the pseudotyping envelope protein VSV-G of the vesicular stomatitis virus (17)], 1 mg of the helper construct pCD/NL-BH* (32) and 1 ml of the desired transgene-encoding lentiviral expression vector were transfected into human embryonic kidney cells (HEK293-T, kindly provided by Andreas Zisch). The medium was replaced after 12±15 h and virus particles were produced for another 48 h. Viral particles were collected from the HEK293-T supernatant by ®ltration through a 0.45 mm ®lter (Schleicher & Schuell GmbH, Dassel, Germany: FP 030/2) yielding typical titers of 2 Q 10 7 c.f.u./ml when titrated on CHO-K1 cells. p24 assays were performed using a commercial kit (NEK-050, Perkin Elmer, Boston, MA) [pMF351, 104.8 T 6.4 ng/ml p24; pLentiModule1, 109.9 T 7.25 ng/ml p24 (triplicate mean values)]. 60 000 target cells per 6-well were infected with 200 ml viral supernatant. Hippocampal slice cultures were infected as described by Ehrengruber and co-workers (37) .
RESULTS
Design of multi-purpose lentiviral expression vectors containing extensive multiple cloning sites
Most lentiviral expression vectors currently available from the research groups, which have pioneered lentiviral transduction technologies are lacking extensive MCS rendering the straightforward design of HIV-1-based expression vectors complicated (16) . We have constructed a versatile lentiviral expression vector family derived from the HIV-1-based SIN pNL-EGFPDU3 (J.Reiser, unpublished data; 38) which contains up to 29 unique sites for restriction endonucleases, many of which are rare-cutting 8 bp-recognizing enzymes. pNL-EGFPDU3 has a classical lentiviral expression vector set-up consisting of 5¢LTR, y+, splice donor (SD), origin of replication of the simian virus 40 (ori SV40 ), central polypurine tract (cPPT), RRE, splice acceptor (SA) and a 3¢LTR DU3 . The P hCMV -EGFP expression cassette is inserted between the SA and the 3¢LTR DU3 using the unique HpaI and KpnI sites (5¢LTR-y+-SD-ori SV40 -cPPT-RRE-SA-HpaI-P hCMV -EGFPKpnI-3¢LTR DU3 ). The ori SV40 is boosting the vector copy number in transiently transfected cells producing SV40 large T antigen, such as HEK293-T cells (17) . A 400 bp EcoRV/ PvuII deletion within the 3¢LTR (3¢LTR DU3 ) inactivates the 5¢LTR promoter upon reverse transcription and integration when the DU3 deletion is transferred to the 5¢LTR in a selfsuf®cient manner, a process also referred to as SIN (25, 26) .
In order to extend the MCS of pNL-EGFPDU3, a PCRampli®ed P hCMV -EYFP cassette¯anked by 26 unique restriction sites was cloned into the HpaI/KpnI sites of pNL-EGFPDU3 and resulted in pMF351 (5¢LTR-y+-ori SV40 -cPPT-RRE-MCSI-P hCMV -EYFP-MCSII-3¢LTR DU3 ; Fig. 1 , Table 1 ). The P hCMV -EYFP was subsequently excised by a NotI deletion resulting in pMF356, a lentiviral expression vector containing 28 unique restriction sites (5¢LTR-y+-ori SV40 -cPPT-RRE-MCS-3¢LTR DU3 ; Fig. 1, Table 1 ). As nonexhaustive examples for the construction kit-like lentiviral expression vector platform a variety of pMF356 derivatives have been designed which contain: (i) a P PGK -driven neomycin resistance gene (neo) (pBM8; 5¢LTR-y+-ori SV40 -cPPT-RRE-MCSI-P PGK -neo-MCSII-3¢LTR DU3 ),
(ii) a strong constitutive human elongation factor 1a promoter (P hEF1a ; pMF359; 5¢LTR-y+-ori SV40 -cPPT-RRE-P hEF1a -MCS-3¢LTR DU3 ), (iii) a P hEF1a -driven EYFP cassette (pMF365; 5¢LTR-y+-ori SV40 -cPPT-RRE-P hEF1a -MCSI-EYFP-MCSII-3¢LTR DU3 ), (iv) a P hEF1a promoter plus a P PGK -neo cassette (pBM9; 5¢LTR-y+-ori SV40 -cPPT-RRE-P hEF1a -MCSI-P PGK -neo-MCSII-3¢LTR DU3 ), (v) a human cytomegalovirus immediate early promoter (P hCMV ; pMF363; 5¢LTR-y+-ori SV40 -cPPT-RRE-P hCMV -MCS-3¢LTR DU3 ) or (vi) a P hCMV -ECFP cassette (pMF371; 5¢LTR-y+-ori SV40 -cPPT-RRE-P hCMV -MCSI-ECFP-MCSII-3¢LTR DU3 ) (see Fig. 1 and Table 1 for all plasmids).
In order to validate this class of multi-purpose lentivectors, a variety of pMF359 derivatives were constructed which encode EPO (pBM42), the vascular endothelial growth factor (VEGF 121 , pBM43) or the SEAP (pBM44) under control of P hEF1a . pBM42-, pBM43-and pBM44-derived lentiviruses were able to drive high-level protein secretion following transduction of CHO-K1 (Table 2) . Also, pMF351-and pMF365-based lentivectors displayed similar transduction ef®ciencies compared with their parental constructs of the pNL-EGFP series (38) (Fig. 2, Table 3 ).
Although the basic lentiviral expression units contained in these expression vectors (pMF351, pMF356, pBM8, pMF359, pMF365, pBM9, pBM363, pMF371; Fig. 1 ) are only~3.5 kb in size, they are¯anked by super¯uous chromosomal regions that are remnants of the integration sites of the ®rst HIV proviruses cloned from the human chromosome [molecular clone HXB2 (39)]. As these chromosomal sites are not packaged and transferred to the target cells, they are not limiting the cargo size of the lentiviral expression units. However, the entire expression vectors may reach the replicative limit when ampli®ed in Escherichia coli.
Elimination of any chromosomal sequences was achieved by PCR-mediated ampli®cation of the lentiviral expression units (5¢LTR-y+-ori SV40 -cPPT-RRE-MCS-3¢LTR DU3 ). AatII and NheI sites engineered in the primer extensions enabled ligation to the pTRIDENT-derived minimal high-copy number vector backbone fragment generated by AatII/XbaI digestion (35, 40) . This cloning procedure resulted in pMF388, a 4.8 kb vector containing a lentiviral expression module with 29 unique restriction sites for convenient integration of desired transgenes (Fig. 3, Table 1 ; pMF388, 5¢LTR-y+-ori SV40 -cPPT-RRE-MCS-3¢LTR DU3 ). Several exemplary pMF388 derivatives have been designed which contain in addition to the basic lentiviral expression unit: (i) a P hCMV -driven EYFP cassette (pMF394; 5¢LTR-y+-ori SV40 -cPPT-RRE-MCSI-P hCMV -EYFP-MCSII-3¢LTR DU3 ), (ii) a P hEF1a promoter (pBM7; 5¢LTR-y+-ori SV40 -cPPT-RRE-P hEF1a -MCS-3¢LTRD U3 ), (iii) a P hEF1a -driven EYFP cassette (pBM40; 5¢LTR-y+-ori SV40 -cPPT-RRE-P hEF1a -EYFP- Figure 4 . Transduction of optimized lentivectors into various insect, chicken, murine and human cell types as exempli®ed by VSV-G-pseudotyped pMF351-derived lentiviruses (Fig. 1) . The gene encoding the EYFP was successfully transduced into Chinese hamster ovary cells (CHO-K1), baby hamster kidney cells (BHK-21), human ®brosarcoma cells (HT-1080), human cervial adenocarcinoma cells (HeLa), human hepatocellular carcinoma cells (HepG2), human chronic myelogenous leukemia cells (K-562), bursal chicken cells (DT40) as well as insect cells (SF9). pMF351-derived lentiviruses also transduced glial cells in hippocampal slice cultures (hippocampal slice) and primary ARC (magni®cation 100Q, hippocampal slice 50Q; ARC 400Q). 3¢LTR DU3 ), (iv) a P PGK -driven neomycin resistance cassette (P PGK -neo; pBM13; 5¢LTR-y+-ori SV40 -cPPT-RRE-MCSI-P PGK -neo-MCSII-3¢LTR DU3 ) or (v) a P hEF1a promoter plus a P PGK -neo cassette (pBM14; 5¢LTR-y+-ori SV40 -cPPT-RRE-P hEF1a -MCSI-P PGK -neo-MCSII-3¢LTR DU3 ) (see Fig. 3 and Table 1 for all plasmids).
Besides the great¯exibility to accommodate almost any desired transgene, the extended MCS of the lentiviral expression vectors shown in Figures 1 and 3 are fully compatible with pQuattro, pTRIDENT, pRetroTRIDENT, pTWIN, pRetroTWIN and pDuoRex type constructs and enable onestep exchange of multicistronic and regulated expression units among these different expression vector families (35,40± 42) . In addition, these vectors facilitate straightforward swapping of cis-acting elements and transgene expression units between each other using: (i) remaining polylinker sites; (ii) unique restriction sites within the (5¢) b-lactamase coding region (bla; AseI, FspI, XmnI, SspI, AatII); and/or (iii) corresponding cisacting elements (EcoRV, NarI, BssHII, XmnI, S®I, StuI, NsiI).
We have tested the construction kit-like lentiviral expression vector platform by infecting various insect (SF9), chicken (DT40), murine (BHK-21, CHO-K1) and human (HeLa, HT-1080, HepG2, K-562) cell lines as well as ARC and hippocampal slices using the pMF351-derived lentivirus (5¢LTR -y+-ori SV40 -cPPT-RRE-MCS-P hCMV -EYFP-MCSII-3¢LTR DU3 ). All cell lines transduced with pMF351-derived lentiviruses show high-level expression of the EYFP while EYFP expression is absent in mock-transduced control cultures. Even ARCs, which are known to be refractory to a variety of transfection/transduction technologies, were readily transduced by the pMF351-derived lentivirus providing an alternative to the recently described Sindbis-based transduction systems (28) . Also, this lentivirus transduced glial cells in rat hippocampal slices (Fig. 4) . In CHO-K1 cells the transduction ef®ciency of pBM4-derived lentiviruses was similar compared with the parental pNL-EGFP and pMF351 vector series (38) (see above and Fig. 2 , Table 3 ).
The biological potential of lentiviral transduction was further exempli®ed by expression of VEGF in chicken embryos. Infection of the chick embryos' CAM with increasing concentrations of pBM43-derived lentiviruses (5¢LTR-y+-ori SV40 -cPPT-RRE-P hEF1a -VEGF 121 -3¢LTR DU3 ) resulted in a dose-dependent VEGF 121 -mediated local induction of new blood vessels demonstrated by increased vascular density, enhanced formation of numerous arterioles and venules as well as by a boost in vessel endpoint and branching density (Fig. 5) . When overdosing VEGF 121 (5 Q 10 6 c.f.u./ml producing 35.5 T 3.8 ng/ml VEGF 121 in 48 h; not shown) or following i.v. application of pBM43-derived lentivirus (1.5 Q 10 6 c.f.u./ml producing 10.6 T 0.9 ng/ml VEGF 121 in 48 h), the hierarchical, tree-like structure of the supplying vessels disappears and the multitude of arterioles and venules adopt an irregular tortuous shape associated with atypical delta-or brush-like vessel endpoints (Fig. 5D ).
Construction of pLentiTRIDENT vectors for tricistronic expression of up to three transgenes
Multicistronic expression technologies for coordinated expression of several transgenes from a single arti®cial eukaryotic operon have generated unprecedented impact in rational reprogramming of mammalian production cell lines and anti-in¯ammation engineering (43, 44) . Particularly in a therapeutic setting when the therapeutic proteins consist of multiple subunits or multiple target/strategy approaches involving ribozymes, antisense RNA, transdominant proteins and intracellular antibodies, multicistronic expression technologies are highly desirable (45) . We have recently pioneered a multicistronic expression vector family, pTRIDENT, which enables tricistronic expression of up to three transgenes from a single constitutive or regulatable promoter. Whereas the ®rst cistron is translated in a classical cap-dependent manner, translation initiation of the second and third cistrons rely on viral cap-independent internal ribosome entry sites of poliovirus (IRES) or encephalomyocarditis virus Figure 6 . pLentiTRIDENT, tricistronic lentiviral expression vectors for simultaneous expression of up to three transgenes. Besides the basic lentiviral cis-acting elements (see Fig. 1 ) pLentiTRIDENT contain a tricistonic expression unit consisting of two IRES or encephalomyocarditis viral origin (CITE*)¯anked by extensive MCS for integration of desired transgenes, for example the ones encoding the cyan (ECFP), red (RFP) and yellow (EYFP)¯uorescent genes (pLentiTFT1 and pLentiTFT2).
(CITE) which had been optimized for maximum translation enhancement (CITE*) (35, 40, 42) .
In order to merge multicistronic expression and lentiviral transduction technology, we have designed the pLenti-TRIDENT vector series, which contains a P hCMV -driven tricistronic eukaryotic operon within a pMF356-derived lentiviral expression cassette (Fig. 6, Table 1 ). pLenti-TRIDENT1/(pLentiTRIDENT2) was constructed by excising the MCSI-IRESI-MCSII-IRESII/(CITE*)-MCSIII cassette of pTRIDENT1/(pTRIDENT3) by EcoRI/BglII and ligating it into the lentiviral transduction unit of pMF363 (EcoRI/ BamHI) [5¢LTR-y+-ori SV40 -cPPT-RRE-P hCMV -MCSI-IRESI-MCSII-IRESII/(CITE*)-MCSIII-3¢LTR DU3 ]. The pLenti-TRIDENT vectors were validated by inserting the genes encoding the (enhanced) cyan, red and yellow¯uorescent proteins into the ®rst, second and third cistrons, respectively, which resulted in the triple-¯uorescent pLentiTRIDENT vectors (pLentiTFT1/(pLentiTFT2). CHO-K1 cells and glial cells in hippocampal slices transduced with pLentiTFT vectors showed simultaneous high-level expression of all three¯uorescent marker proteins (Fig. 7) .
pLentiModule, an advanced highly modular lentiviral expression system Previous lentiviral expression vectors have been designed for optimal integration of desired transgenes by engineering of extended MCS. However, lentiviral transduction units have been successfully modi®ed in the past years to optimize speci®c cis-acting modules for: (i) Tat-independent production of lentiviruses by replacement of the 5¢LTR enhancer region (19, 23, 26, 46) ; (ii) optimization of packaging signal and Rev-responsive elements (47, 48) ; and (iii) replacement of the enhancer sequences of the 3¢LTR by LoxP sequences for conditional site-speci®c excision of transduced expression units (49) or by antibiotic-responsive operator modules for conditional proviral gene expression (46) .
In order to combine minimal lentiviral transduction modules with extended polylinkers and the highest¯exibility for advanced modi®cation of the cis-acting elements we designed a novel modular lentivector (pLentiModule) which consists of four modules: (i) XhoI/NruI-U3 1 -StuI/SbfI/PstI-U3 2 -SrfI, (ii) SrfI-R-U5-y+-SD-SwaI/NsiI, (iii) SwaI/NsiI-cPPT-RRE-SA-MCSI and (iv) MCSI-3¢LTR DU3 (1)-MCSII-3¢LTR DU3 (2)-MCSIII. These modules are¯anked by unique restriction sites and were sequentially assembled into a minimal pTRIDENT-derived prokaryotic vector backbone to result in pLentiModule1 [XhoI/NruI-U3 1 Fig. 8 , Table 1 ]. In contrast to the previously described lentivectors pLentiModule is devoid of the ori SV40 since transfer of this simian virus element into target cells is incompatible with current therapeutic modalities.
pLentiModule1 displays a construction kit-like highly modular structure and enables design of the following lentivector characteristics. (i) Transfer of the entire lentiviral expression cassette using the¯anking unique sites XhoI/NruI and MCSIII, (ii) exchange of the 5¢U3 region by XhoI/NruI and SrfI, (iii) switching of the 5¢U3 enhancer (Tat-binding) sequences by XhoI/NruI and StuI/SbfI/PstI, (iv) substitution of the R-U5-y+-SD module using SrfI and SwaI/NsiI, (v) replacement of the cPPT-RRE-SA module by modi®ed counterparts using the SwaI/NsiI and MCSI sites, (vi) cloning of desired transgenes, promoters and resistance cassettes into MCSI which is also compatible with the pLentiTRIDENT vectors and all of the previously described lentivectors (Figs 1, 3 and 6), (vii) swapping of the 3¢LTR DU3 element using sites contained in MCSI and MCSIII and (viii) integration of functional units (for example, LoxP, tissue-speci®c or regulatable operators, insulator sequences) into MCSII which are copied into the 5¢LTR upon reverse transcription and integration. In addition, (ix) cassette swapping with all other vectors described here is further facilitated using any of the sites within the bla region (AseI/FspI/XmnI/SspI/AatII) and the R-U5-y+-SD module (NarI/BssHII/XmnI).
pLentiModule1 was tested by insertion of a P hCMV -EYFP cassette into its MCS (pLentiModule2; Fig. 6 , Table 1 ) and transduction into insect (SF9), chicken (DT40), murine (BHK-21, CHO-K1) and human (HeLa, HT-1080, HepG2, K-562) cell lines as well as into ARCs and glial cells of hippocampal slice cultures (Fig. 9) . Furthermore, pLentiModule1-derived lentivectors encoding EPO (pLentiModule7), VEGF 121 (pLentiModule6) or SEAP (pLentiModule8) under control (Tables 2 and 3) .
As pLentiModule1 and pLentiModule2 are devoid of ori SV40 , the virus titer is signi®cantly reduced to the ones generated using an intact ori SV40 /large T antigen replication system (Table 3) . We have therefore inserted a 168 bp fragment spanning the ori SV40 into MCSIII of pLentiModule1 and pLentiModule2, respectively, resulting in pLentiModule3 and pLentiModule4. As quanti®ed from CHO-K1 transductions, ori SV40 -containing pLentiModule derivatives achieve Figure 8 . Modular SIN lentiviral expression vectors. In order to facilitate the design of advanced lentiviral expression vectors, all cis-acting lentiviral sequences are¯anked by unique restriction sites in pLentiModule vectors (XhoI/NruI-U3-SrfI; SrfI-R-U5-y+-SD-SwaI/NsiI; SwaI/NsiI-cPPT-RRE-SA-MCS; MCS-3¢LTR DU3 -NdeI/NheI/SalI/XbaI). Unique restriction sites have also been placed within U3 (StuI, SbfI, PstI) and at the site of the deletion within 3¢LTR DU3 (PmeI, HpaI, BclI). In order to enhance virus production an ori SV40 (origin of replication of the Simian virus 40) has been placed 3¢ of the 3¢LTR outside of the lentiviral expression unit. Test lentivectors pLentiModule2 and pLentiModule3 contain a P hCMV -driven EYFP expression cassette in the central MCS.
virus titers, which compares to aforementioned lentivectors (Fig. 2, Table 3 ).
DISCUSSION
Since their discovery in the early 1980s, HIV-1 lentiviruses were known to cause one of the most devastating epidemics in industrialized countries in recent history (50, 51) . However, the unique characteristic of HIV-1 to transduce and integrate into the human genome owing to a set of accessory genes managing nuclear import has brought this deadly virus into the limelight of the gene therapy arena as most genetic defects in humans reside in non-proliferating terminally differentiated cells. As the ®rst development of replication-incompetent HIV-1-based vectors to transduce mitotically inert rat neurons, human skin ®broblasts and CD34 + cells (16, 17) , lentiviral transduction technologies have witnessed a progress to the top of currently most promising gene therapy initiatives.
Elimination of some 60% of its genome (including all accessory genes) and re-assembly in multiply attenuated splitgenome packaging systems successfully addressed legitimate initial safety concerns. The most advanced lentiviral transduction systems include a third-generation packaging system consisting of a (i) gag-pol, (ii) rev and (iii) a vesicular stomatitis virus-derived envelope protein (VSV-G) as well as (iv) a SIN lentiviral expression vector. The split-genome strategy dramatically reduces the emergence of replicationcompetent recombinants and pseudotyping eliminates targeted infection of CD4 + T lymphocytes as well as extension of the cell tropism for therapeutic interventions (19) . However, for successful infection of some target tissues including the liver some accessory proteins such as Vpr and Vif may be essential and should be considered for the packaging set-up (9) . Typically, replication-incompetent lentiviral particles are produced by co-transfecting a helper cell line with all packaging and the lentiviral expression vector. However, with pharmaceutical production of therapeutic lentiviruses in mind a variety of different stable packaging cell lines have been designed which produced replication-incompetent transgenic lentiviruses in a tetracycline-responsive manner (20±23).
The lentiviral expression unit is the only genetic material transferred to the target cells and encodes the desired therapeutic transgene. This expression vector contains only cis-acting sequences and is devoid of any lentiviral coding sequences, which prevents signi®cant humoral immune responses. Major improvements of lentiviral expression vectors include: (i) elimination of enhancer sequences from the 3¢LTR which results in complete loss of the 5¢LTR's transcriptional capacity and the viral mobilization competence upon integration of the provirus in the target chromosome thereby increasing safety and minimizing interferences with internal and chromosomal promoters in vivo and (ii) replacement of 5¢LTR promoters by heterologous promoters to achieve Tat-independent and/or tetracycline-responsive virus production (23, 25, 26, 49) . Many of these state-of-the-art lentivectors have been successfully used in pioneering gene therapy studies for the treatment of many prominent human diseases in animal models including Parkinson's disease and metachromatic leukodystrophy (8, 10) .
Despite the dramatic progress in lentivector development in recent years lentiviral expression con®gurations available from the pioneering research groups have been rather specialized and inconvenient for straightforward design of multi-purpose lentivectors by a broad scienti®c community. We have therefore designed a highly modular construction kitlike expression platform based on the latest generation SIN lentivectors for mono-and multicistronic expression in a variety of cell lines and primary cells including, for the ®rst time, ARCs. Also, to our knowledge, we report here the ®rst lentiviral transduction into chicken embryos. This simple-touse multi-purpose lentivector expression platform, which is compatible with any of the aforementioned packaging concepts is expected to greatly facilitate the use of lentiviral transduction technologies by a wider scienti®c community to accelerate the advancement in gene therapy and tissue engineering. 
